Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS INC (REGN), sold 26,362 shares at $462.72 ($12.4M) on 2017-06-15, disclosed to the SEC on 2017-06-16.
Open-market sale of $12.4M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $475.56 | 906 | $431K | 3.5% |
| 2 | $475.56 | 10,822 | $5.1M | 41.4% |
| 3 | $462.72 | 500 | $231K | 1.9% |
| 4 | $463.91 | 100 | $46K | 0.4% |
| 5 | $464.69 | 400 | $186K | 1.5% |
| 6 | $465.49 | 1,244 |
| $579K |
| 4.7% |
| 7 | $465.49 | 1,244 | $579K | 4.7% |
| 8 | $466.52 | 185 | $86K | 0.7% |
| 9 | $466.52 | 185 | $86K | 0.7% |
| 10 | $467.82 | 300 | $140K | 1.1% |
| 11 | $468.63 | 900 | $422K | 3.4% |
| 12 | $469.53 | 2,212 | $1.0M | 8.4% |
| 13 | $469.53 | 2,212 | $1.0M | 8.4% |
| 14 | $470.57 | 2,426 | $1.1M | 9.2% |
| 15 | $470.57 | 2,426 | $1.1M | 9.2% |
| 16 | $471.15 | 100 | $47K | 0.4% |
| 17 | $472.95 | 100 | $47K | 0.4% |
| 18 | $474.48 | 100 | $47K | 0.4% |
| Total | $471.74 avg | 26,362 | $12.4M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |